Toward personalized treatment approaches for non-small-cell lung cancer
M Wang, RS Herbst, C Boshoff - Nature medicine, 2021 - nature.com
Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …
Acquired resistance to immune checkpoint inhibitors
AJ Schoenfeld, MD Hellmann - Cancer cell, 2020 - cell.com
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
M Yuan, LL Huang, JH Chen, J Wu, Q Xu - Signal transduction and …, 2019 - nature.com
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
Cancer immunoediting and resistance to T cell-based immunotherapy
JS O'Donnell, MWL Teng, MJ Smyth - Nature reviews Clinical oncology, 2019 - nature.com
Anticancer immunotherapies involving the use of immune-checkpoint inhibitors or adoptive
cellular transfer have emerged as new therapeutic pillars within oncology. These treatments …
cellular transfer have emerged as new therapeutic pillars within oncology. These treatments …
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
Lung cancer in China: current and prospect
F Wu, L Wang, C Zhou - Current opinion in oncology, 2021 - journals.lww.com
Lung cancer in China: current and prospect : Current Opinion in Oncology Lung cancer in
China: current and prospect : Current Opinion in Oncology Log in or Register Subscribe to …
China: current and prospect : Current Opinion in Oncology Log in or Register Subscribe to …
[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …